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The side effect profile of sirolimus: A phase I study in quiescent
cyclosporine-prednisone-treated renal transplant patients. A 14-day as-
cending dose course of sirolimus (rapamycin, RAPA) was administered to
quiescent renal transplant patients receiving a double-drug cyclosporine
(CsA)/corticosteroid regimen in a double-blinded randomized study. Oral
sirolimus or placebo was delivered twice daily in divided doses for 13 days
and a final dose was administered on the morning of study day 14. In
addition, patients in the sirolimus- and placebo-treated groups were
compared with a demographically matched, concurrently treated control
cohort of 30 patients who received the same concentration-controlled
CsAlcorticosteroid regimen. The study cohort was partitioned into four
sirolimus dose level groups: placebo (0 mglm2/day, N = 10), low dose (1
to 3 mg/m2/day, N = 9), medium dose (5 to 6 mg/m2/day, N = 9), and high
dose (7 to 13 mg/m2/day, N 12). The primary side effect of sirolimus was
a reversible decrease in platelet (PLT) and white blood cell (WBC) counts.
Cholesterol values increased statistically significantly in the sirolimus-
treated patients when compared with those of the placebo patients, but
not when compared with those of the control group patients. There were
no statistically significant differences in the steady-state average concen-
trations of CsA among sirolimus dose groups (including placebo). No
differences were observed between the pre- and post-sirolimus treatment
values of systolic and diastolic blood pressure values, glomerular filtration
rates (GFR), serum creatinine values (Sr), and serum glutamic oxaloa-
cetic transaminase (SGOT), serum glutamic pyruvic transaminase (SGPT)
or triglyceride levels. Because the principal side effects of sirolimus are
distinct from the principal nephrotoxic properties of CsA, this drug
combination may display potent immunosuppression without exacerbated
toxicity.
Drug combination strategies wherein CsA is administered in
conjunction with other agents seek to maximize the immunosup-
pressive and minimize the adverse side effects of cyclosporine
(CsA; Sandimmune, Sandoz, SZ) [1—31. Sirolimus (RAPA, rapa-
mycin; Rapamune , Wyeth-Ayerst Research, Radnor, PA,
USA), a carboxycyclic lactone-lactim macrolide produced by
Streptomyces hygroscopicus, was first identified as an anticandidal
agent [4, 5] and subsequently was explored as an immunosuppres-
sant [61. In several animal models sirolimus prolongs graft survival
[7—9] and inhibits the development of systemic lupus erythemato-
sus, experimental allergic encephalomyelitis and adjuvant arthritis
[10, 11] at doses that are markedly lower than those required of
GsA. The combination of sirolimus and CsA inhibits the immune
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response synergistically [12], perhaps due to the sequential bio-
chemical effects of these two drugs on T cells. CsA inhibits the
transcription of lymphokine genes by blocking the generation of
proteins that regulate induction of cytokine transcription, thereby
preventing the progression of T cells from the G0to the G1 phase
of the cell cycle. Sirolimus inhibits the G1 build-up by inhibiting
the intracellular activity of a range of kinases, including phos-
phatidyl inositol kinases, p70S6 kinase kinase and p34'2 kinase
[13—18]. Because the sirolimus/CsA combination is likely to
proffer potent immunosuppression for human organ transplanta-
tion [19], the Phase I study presented herein assessed the safety
and tolerance of ascending multiple doses of sirolimus adminis-
tered to quiescent renal transplant patients under simultaneous
CsA and corticosteroid (prednisone; Pred) treatment, with special
regard to renal and liver function tests, systolic and diastolic blood
pressure values, cholesterol and triglyceride levels, as well as
myelopoiesis.
Methods
Patients
After approval by our institutional Committee for the Protec-
tion of Human Subjects, the present study was conducted in 43
quiescent renal transplant patients who for at least six months had
borne well-functioning allografts, as defined by glomerular filtra-
tion rates (GFR) > 40 ml/min. All patients had been maintained
for at least three months on CsA oral doses that achieved stable
therapeutic blood levels, as assessed by CsA average steady state
concentrations (CSSav) [20] and an average Pred dose of 13.56
4.01 mglday (mean SD). The oral doses of CsA in patients on
once daily regimens ranged from 225 to 500 mg, whereas oral CsA
doses in patients on twice-a-day regimens ranged from 75 to 400
mg.
These patients were randomized in blinded fashion; 32 patients
received sirolimus and 11 patients received placebo treatment.
Soon after the study initiation, two patients (1 on sirolimus and 1
on placebo) voluntarily discontinued participation, and at the
immediate pre-study screening of blood chemistries one siroli-
mus-treated patient displayed values that exceeded normal limits.
Table 1 summarizes the demographic characteristics of the 40
patients (30 on sirolimus and 10 on placebo) as well as of an
additional 30 non-randomized control group patients who had
been transplanted at approximately the same time, concurrently
maintained on CsAJPred and demographically matched based
upon age, length of pre-transpiant dialysis, and CsA C55av.
Thirty-three patients (25 of 30 on sirolimus and 8 of 10 on
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Table 1. Demographic characteristics of all patients
Randomized cohorts Historical
control
cohortRAPA Placebo
N 30 10 30
Male/female 20/10 6/4 16/14
Mean age years 42.07 9.35 42.20 7.87 40.53 8.20
Ethnic groups
Caucasian 18 5 20
African-American 10 5 9
Asian 2 0 0
Native American 0 0 1
Primary renal disease
Diabetes mellitus 7 4 4
Hypertension 12 4 7
Systemic lupus 1 0 0
erythematosus
Nephrolithiasis 1 0 1
Glomerulonephritis 2 0 7
Polycystic kidney disease 1 0 3
Malformation 1 0 0
Pyelonephritis 1 1 4
Unknown etiology 4 2 6
Prior dialysis
Hemodialysis 26 7 22
Peritoneal dialysis 3 2 2
Pre-emptive 1 1 6
Mean length of dialysis 15.9 15.4 19.4 15.8 20.5 38.7
months
Donor source of kidney
Cadaveric 21 8 20
Living-related 9 2 10
Retransplant 1 4 1
All groups showed not
chi-squared tests
significant differences by Student's t- or
placebo) were receiving chronic therapy for pre-existent hyper-
tension that included calcium channel blockers (CCB) in 31
patients, 13-blockers in 17, clonidine in 7, prazosin in 6, and
hydralazine in 2 patients. Among the sirolimus-treated patients,
11 were on one drug, 8 on two drugs, 4 on three drugs, and 2 on
four drugs for anti-hypertensive therapy. Among the placebo
patients, 3 were on one drug, 2 on two drugs, and 3 on three drugs.
Seven patients (6 on sirolimus and 1 on placebo) were receiving
gemfibrozil for hypertriglyceridemia, and 4 patients (all on siroli-
mus) were receiving pravastatin for hypercholesterolemia. Twen-
ty-six patients in the concurrent, non-randomized control group
were treated with chronic anti-hypertensive therapy (20 with
CCB, 12 with 13-blockers, 6 with clonidine, 4 with prazosin, and 1
with hydralazine), 2 patients were receiving gemfibrozil and none
was receiving pravastatin. Among the control patients, 10 were on
one drug, 13 on two drugs, 1 on three drugs, and 1 on four drugs.
Drug formulation
Oral sirolimus (5 mg/ml) was provided in a non-aqueous
mixture obtained from Wyeth-Ayerst Research. The concentrate
was protected from light and refrigerated in 5 ml flint vials that
enabled withdrawal of 2.5 ml. The sirolimus dose was determined
based upon body surface area (mg/m2). The final solution was
prepared in a glass vessel by diluting the appropriate volume of
sirolimus concentrate with approximately two ounces of sterile
water, and vigorously stirring for at least one minute. An equal
volume of placebo was supplied by Wyeth-Ayerst Research as a
non-aqueous mixture that contained identical excipients and was
also diluted with water.
Study design
After the initial screening two weeks before entry, patients were
randomized to receive either oral sirolimus (1.0, 2.0, 3.0, 5.0, 6.0,
7.0, 8.0, 10 and 13 mg/rn2 total daily dose) or placebo in blinded
fashion twice daily in divided doses for 13 days and on the
morning of study day 14. Each dose cohort included three patients
randomized to receive active drug and one patient to receive
placebo. Because the first four patients treated with 5 mg/rn2
seemed to display an excess of side effects, an additional four
patients were enrolled into this group before administering the 6.0
mg/m2 dose. The present analysis divided the sirolimus-treated
patients into three dose level groups: the low dose group received
1 to 3 mg/m2/day (N = 9); the medium dose group, 5 to 6
mg/m2/day (N = 9); and the high dose group, 7 to 13 mg/m2/day
(N = 12). Patients were combined into the three dose level groups
(low, medium and high) in order to make comparisons between
groups with similar numbers of patients. Patients in these three
groups did not differ in mean age, length of time on pre-transpiant
dialysis, time post-transplant, CsA dose, or CsA Css, (data not
presented).
Patients were monitored for adverse effects before, during and
two weeks after drug administration. Vital signs were measured
and physical examinations were performed during the study.
Complete laboratory determinations included fasting serum con-
centrations of cholesterol, triglycerides, creatinine (Scr), glutamic
oxaloacetic transaminase (SGOT), and glutamic pyruvic transam-
inase (SGPT), as well as white blood cell (WBC) and platelet
(PLT) counts. Exclusion criteria included values of SGOT and
SGPT that were greater than two times the upper limits of the
laboratory's normal range, as well as WBC <4000/mm3 and PLT
< 150,000/mm3. Patients were considered to be hyperlipidemic if
the cholesterol value was  200 mg/dl and/or the triglyceride
value was > 250 mg/dl. The day 14 analyses did not include the
four patients discontinued before the conclusion of the study,
because of increased triglyceride levels in one siroiimus-treated
patient and increased S. values in three placebo-treated patients.
Glomerular filtration rate
lohexol (180 or 140 mg I/mi; Omnipaque, Winthrop Pharma-
ceutical Co., NY, USA) doses were calculated for i.v. injection
based upon a nomogram that related estimated creatinine clear-
ance to a target plasma iodine concentration of  0.1 mg/mI at the
three- and four-hour post-injection times of peripheral venous
blood sampling (7 cc/sample). Using the Renalyzer TM PRX9O
(Provalid AB, Lund, Sweden), X-ray fluorescence was used to
estimate the iodine concentration in plasma separated from whole
blood samples that had been drawn into heparinized tubes. This
method did not require urine collections [21, 22].
CsA pharmacokinetic parameters
Whole blood samples drawn into tubes containing sodium
ethylenediametraacetic acid (EDTA) were analyzed for CsA
concentrations by a fluorescence polarization immunoassay with a
quantitation limit of 25 ng/ml using a selective monoclonal
antibody (TDx, Abbott, N. Chicago, IL, USA). The steady state
area under the concentration-time curve (AUC) was estimated by
the log-trapezoidal rule. In patients receiving oral CsA once daily,
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Table 2. Dose relation of laboratory determinations in RAPA subgroups
Date
Placebo
0 mg/rn2 /day
All RAPA
dose groups
Low dose
1—3 mg/rn2 /day
Medium dose
5—6 mg/m2/day
High dose
7—13 mg/rn2 /day
N 10 30 9 9 12
Age years 42.20 7.87 42.07 9.35 43.67 9.08 43.00 9.80 41.6 10.4
Length of dialysis months 19.4 15.8 15.9 15.4 21.4 15.0 13.9 12.5 13.2 17.9
PLT cell/mm3 entry 250.8 63.5 238.7 62.9 223.1 65.6 225 103 253.3 60.8
WBC cell/mm3
day 15
entry
day 15
271.0 84.6
10.58 3.72
9.83 2.95
169.1 74•9a
7.87 2.45"
5.96 2.73"
209.2 89.61"
7.27 2.39a
5.87 1.74"
143.8 29.7"
7.49 1.90"
5.05 1.22"
155.8 76.8a
8.51 2.69
6.64 3.83"
Cholesterol mg/dl entry
day 15
242.3 48.2
207.3 27.8
256.6 62.6
264.1 63.3a
249.4 51.2
249.1 81.7
272.9 62.6
275.1 64.1"
251.7 72.4
271.6 68.4"
Triglycerides rng/dl entry
day 15
214.9 77.9
244.9 95.1
234 138
264 139
210 129
191 108
270 195
316 183
223.8 92.2
286 108
Sr rng/dl entry
day 15
1.70 0.537
1.64 0.520
1.64 0.48
1.64 0.49
1.85 0.64
1.71 0.61
1.56 0.42
1.50 0.40
1.55 0.38
1.70 0.49
GFR ml/rnin/1.73 m2
SGOT IU
entry
day 15
entry
day 15
57.4 17.3
51.1 15.2
18.40 6.47
16.00 4.50
53.5 12.4
51.9 19.4
20.9 20.2
22.5 11.6
51.22 9.55
50.0 16.4
24.8 19.3
24.8 12.4
58.1 13.4
62.1 27.2
17.44 8.90
23.4 13.8
51.7 13.5
45.4 11
19.4 11.31
20.00 9.60
SGPT JU entry
day 15
17.50 5.15
18.44 5.66
22.9 20.2
23.3 14.5
25.4 24.3
24.8 16.6
23.3 23
25.1 18.2
16.22 7.85
20.8 10.2
"P < 0.05 vs. placebo
whole blood CsA concentrations were measured prior to and at
0.33, 0.67, 1, 2, 3, 5, 8, 12, and 24 hours after drug administration.
In patients receiving oral CsA twice daily, the estimate of AUC
was based on the corresponding nine time-points during the 12
hour dosing interval. The CSSV was calculated by correcting the
AUC for the dosing interval T, namely AUC/T. The apparent oral
clearance of CsA (CL/F) was normalized for body wt (kg) as CL/F
= Dose/(AUC kg) [20].
Data analysis
The statistical significance between results presented as mean
SD was assessed using Student's paired t-tests. Proportions were
compared using the Chi-square test. Data were considered statis-
tically significant if P < 0.05. Regression analysis was used to
examine the relationship between the administered dose of siroli-
mus and the study day 15 value of each of nine selected laboratory
parameters, namely PLT count, WBC count, cholesterol, triglyc-
erides, CSSav, GFR, S, SGPT and SGOT. The regression analysis
provided a statistical test of the ability of the independent variable
(or variables) to predict the value of the dependent variable. The
P values provided estimates of the probability that the observed
predictive ability was due to chance. In addition, the descriptive
R2 statistic estimated the proportion of the variance in the
dependent variable that was predicted (or "accounted for") by the
independent variable(s) in the model. Regression analyses with
two independent variables were performed to determine whether
an additional independent variable significantly changed the
relationship between sirolimus dose and a lab parameter. For
example, one model tested the effect of sirolimus on the lab
parameter after accounting for the baseline values for that
parameter in order to exclude pre-existing differences among
subjects that could disguise a relationship or falsely make it
appear that one exists. Two similar analyses failed to show an
impact of recipient age or months on dialysis on the outcome of
sirolimus treatment. Analyses of variance and covariance (AN-
COVA) were used in cases wherein linear regression procedures
were inappropriate.
Results
Effects of sirolimus treatment on platelet counts
Platelet (PLT) counts showed the clearest evidence of a dose-
dependent toxicity during sirolimus treatment. The mean baseline
value of all patients in the sirolimus group ([238.7 62.9] X iO
cells/mm3) decreased at day 9 to 202.7 62.9 cells/mm3 (P =
0.032), at day 12 to 185.6 71.1 cells/mm3 (P = 0.0043), and at
day 15 to 169.1 74.9 cells/mm3 (P = 0.0003; Table 2). Only
sirolimus-treated patients showed a decrease in PLT values. The
effect appeared to be dose-related: PLT counts declined to a
greater extent in patients treated with medium- and high-doses of
sirolimus (Table 2). Neither bivariate nor high order polynomial
terms, which allow for fitting curved lines, described a predictive
model for the relation of dose to decreased PLT count. Upon
discontinuation of sirolimus, PLT numbers returned to baseline
values within two weeks (Fig. 1). There were no statistically
significant differences in the values of mean PLT volume before,
during or after sirolimus treatment (data not shown).
Effects of sirolimus treatment on white blood cell counts
There was a statistically significant, but not entirely dose-
related, decrease in the mean white blood cell (WBC) count after
sirolimus administration. The mean WBC count in all sirolimus-
treated patients was significantly lower than placebo-treated sub-
jects during the study compared with values at study inception:
6.58 1.80 versus 9,41 2.20 cells/mm3 at day 9 (P = 0.0049),
6.51 2.46 versus 10.32 3.42 cells/mm3 at day 12 (P = 0.016),
and 5.96 2.73 versus 9.83 2.95 cells/mm3 at day 15 (P =
0.0044; Table 2). No individual patient displayed a baseline WBC
count less than 4800 cells/mm3, and the mean values of all patients
in each sirolimus dose group were greater than the lower limit of
4800 cells/mm3 on day 15. However, six sirolimus-treated patients
had WBC counts less than 4500 cells/mm3, and two patients had
WBC counts equal to 4500 cells/mm3 (mean 3.58 0.41 cells!
mm3; data not shown). For individual patients the baseline WBC
count was a significant positive predictor of the day 15 value.
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Fig. 1. PLT values in patients receiving sirolimus •) versus placebo (0).
The values of all treated patients before (day 0), during (days I to 14) and
after (days 30 and 45) the study are shown. Sirolimus-treated patients
displayed a significant decrease in PLT values on days 9 (P = 0.032), 12 (P
= 0.0043) and 15 (P = 0.035) compared to baseline values, and on day 15
compared to placebo-treated patients (P = 0.035). The PLT values of
sirolimus-treated patients returned to baseline levels at two weeks after
discontinuation of the drug.
However, even after accounting for the significantly higher base-
line WBC values among placebo-treated patients, which can only
be ascribed to a random event, the entire cohort of sirolimus-
treated subjects showed significantly lower WBC counts (f = 4.94
with one day• f; P = 0.03).
Effects of sirolimus treatment on cholesterol
By three months post-transplant 40% of CsA/Pred-treated
transplant patients display lipid abnormalities. By six months this
disorder affects more than 70% of patients [23]. Indeed, the mean
baseline cholesterol value in the 40 patients treated herein was
greater than the upper limit of the normal range, namely 200
mg/dl. Similarly, the mean baseline cholesterol value in the
control cohort was 261.5 56.8 mgldl. At the inception of the
study, the mean baseline cholesterol value was slightly, but not
significantly higher in patients randomized to receive sirolimus
compared with those who were to receive placebo: 256.6 62.2
versus 242.3 48.2 mg/dl. Univariate analysis, as presented in
Table 2, showed that at day 15 the mean cholesterol level of all
sirolimus-treated patients was higher than that of placebo-treated
patients (264.1 63.3 vs. 207.3 27.8 mgldl; P = 0.0007). Of all
sirolimus-treated patients 20% (6 patients) displayed mean cho-
lesterol values that increased by more than 25% above baseline
values, and 10% (3 patients) by more than 50% above baseline
values. One patient whose cholesterol value increased by more
than 50% above the baseline value was discontinued from the
study due to concomitant high triglyceride levels. Only one
placebo-treated patient (10%) showed an increase, and that
increase was less than 25% above the baseline cholesterol value.
Although these findings suggest that sirolimus treatment was
associated with significant increases in cholesterol, multivariate
analysis showed that this relation only nearly reached significance
(P = 0.052; Table 3). However, when the day 15 data were
analyzed based upon the change from the baseline values, the
regression equation showed a reasonable fit (P = 0.048, Fig. 2).
Effects of sirolimus on triglycerides
In the control cohort the mean baseline triglyceride value was
225 113 mg/dl. At the inception of the study, the mean baseline
triglyceride value was slightly, but not significantly, higher in
patients randomized to receive sirolimus compared with those
who were to receive placebo: 234 138 versus 214.9 77.9 rng/dl
(Table 2). At days 9, 12 and 15 the mean triglyceride value among
all sirolimus-treated patients was not significantly higher than that
of the placebo-treated patients, and more specifically, no individ-
ual sirolimus dose level group displayed a significantly higher
mean triglyceride value than the placebo cohort (Table 2). Among
all sirolimus-treated patients 43% (13 patients) displayed mean
triglyceride values that were increased by more than 25%, of
which 27% (8 patients) increased by more than 50% above
baseline values. Similarly, 40% (4 patients) of placebo-treated
patients showed mean triglyceride levels that increased by more
than 25%, of which 20% were increased by more than 50% above
baseline values. Thus, the changes in triglyceride levels after
sirolimus treatment were not considered significant. Indeed, all
sirolimus-treated patients who displayed a greater than 25%
increase in triglyceride levels at day 15, a mean triglyceride level
of 466 233 mgldl, showed concomitant increases in cholesterol
values, a mean cholesterol level of 305.1 75.9 mg/dl.
The sirolimus- and placebo-treated groups were well-matched
demographically with respect to factors that reportedly contribute
to the appearance of hyperlipidemia in quiescent renal transplant
patients, namely gender, age, time on dialysis, S, GFR, CsA
CSSav, SGOT, SGPT or the administration of /3-blockers or
furosemide (data not shown). Furthermore, there was no obvious
relation between the mean sirolimus dose associated with the
onset of a hyperlipidernic (6.14 3.48 mg/rn2), isolated high
cholesterol (5.11 3,06 mg/rn2) or normolipidemic (6.86 4.49
mg/rn2) state (data not shown). There were significantly greater
decreases in PLT and in WBC values among hyperlipidemic
versus non-hyperlipidemic subjects: 194 89 versus 119 24.9
and 5.66 2.31 versus 6.93 1.95 cells/mm3 (P = 0.05).
Lack of effects of sirolimus treatment on glomerular filtration
There were no statistically significant differences among the
mean GFR values of all patients at the beginning and at the
completion of the study between sirolimus-treated (53.5 12.4 vs.
51.9 19.4 mg/dl) and placebo-treated (57.4 17.3 vs. 51.1
15.2 mg/dl) cohorts (Fig. 3). In addition, there were no statistically
significant differences among the mean GFR values displayed by
each dose level group and all sirolimus- or placebo-treated
patients at the beginning and at the completion of the study.
Furthermore, the 5Cr values of patients in all sirolimus dose level
groups were similar to those of patients in the placebo cohort both
before and after drug administration. Also, the mean Sr values in
all study groups (placebo, low-, medium-, and high-dose siroli-
mus) were similar to those of the control cohort, namely 1.7 +
0.46 mg/dl (data not shown). Four sirolimus-treated individuals
showed a modest and statistically insignificant increase in Sr
(maximum mean SCr of 2.35 0.49 mg/dl) above baseline values
(mean 5Cr of 1.80 0.28 mg/dl) on day 15; however, none of the
subjects was discontinued from the study, and all patients' 5Cr
values returned to the baseline value within seven days. In
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Table 3. Summary statistics for the association of sirolimus therapy with laboratory measurements
Laboratory parameter
Simple regression analysis Multiple regression analysis including baseline
r2
/3
Intercept
Pvalue
for doser2 /3 dose Intercept
P
value Baseline Dose
SOOT IU 0.00 0.11 20.5 0.797 0.49 0.63 0.36 7.4 0.389
SGPT IU 0.00 0.03 22.0 0.951 0.39 0.49 0.24 11.4 0.663
Scr mg/dl 0.00 —0.01 1.7 0.782 0.61 0.83 0.01 0.2 0.389
GFR ml/min/1.73 m2 0.00 —0.11 52.2 0.897 0.07 0.38 0.40 28.3 0.666
CsA conc. nglml 0.00 —1.29 413.4 0.790 0.06 0.23 —0.02 316.8 0.997
Triglycerides mg/dl 0.03 5.50 234.9 0.352 0.09 0.30 6.26 166.5 0.285
Cholesterol mg/dl 0.06 4.15 234.7 0.174 0.42 0.68 4.83 58.8 0.052
WBC 103/mm3 0.05 —0.18 7.7 0.179 0.35 0.60 —0.11 2.2 0.314
PLT 1O/mm3 0.21 —9.75 235.8 0.005 0.31 0.37 —10.32 151.6 0.002
0
ci,
0
0
200
100
0
—100 I I I I I I I
0 1 2 3 4 5 6 78 910111213
RAPA dose, mg/rn 2/day
Fig. 2. Regression analysis of the relation of total daily sirolimus dose to
change in serum cholesterol value (.mg%) from baseline to day 15. The
simple regression equation for the cholesterol change = —22.13104 +
5.140288 (dose) with a value of P = 0.048.
contrast, three placebo-treated patients, all of whom were with-
drawn from the study, showed increased Srvalues before com-
pletion of the study, namely from 2.03 0,32 to 3.23 0.58 mg/dl;
P = 0.053).
Effect of sirolimus treatment on blood pressure
The blood pressure response was monitored over a six-week
period, namely before, during, and four weeks after completion of
the treatment course. Table 4 shows that there were no statisti-
cally significant differences among the mean systolic and diastolic
blood pressure values of all patients. The mean values of the
maximum systolic and diastolic blood pressures among sirolimus-
treated patients during the study (163.4 19.0 and 96.1 12.0,
respectively) were not statistically different from the values of the
placebo-treated patients (151.5 25.8, P = 0.20; and 93.6 12.9,
P = 0.60; respectively). Seven sirolimus-treated individuals dis-
played normal blood pressure values without the need for medi-
cations throughout the course of the study. Fourteen sirolimus-
treated patients showed stable blood pressure values on their
usual anti-hypertensive regimens during sirolimus treatment.
Seven of 30 sirolimus-treated patients showed an increase in
blood pressure to systolic values > 170 mm Hg and diastolic
values> 100 mm Hg, but only three of these patients continued
to require additional medication after sirolimus discontinuation.
Among the 10 placebo-treated subjects, two patients displayed
increased blood pressure values above 170/100 mm Hg during the
course of the study, one of whom required additional medication
at the end of the study. Therefore, sirolimus did not appear to
exacerbate the hypertensive response caused by CsA and cortico-
steroids.
Effects of sirolimus treatment on CsA pharmacokinetic parameters
Table 5 shows the apparent CsA oral clearance rates (CL/F)
and C5Sav on the day before (day —1) and on the last day of (day
14) treatment with sirolimus. Although there was no difference in
CL/F among the four dose groups at baseline before sirolimus
administration (P = 0.075), ANCOVA analysis showed that there
was a significant difference in baseline-corrected CL/F on day 14
of sirolimus administration (P = 0.029). Multiple comparison
analysis based on Tukey's studentized range test showed that the
CL/F values for patients in the sirolimus low-dose group (1 to 3
mg/m2/day) were significantly greater than those of patients in
either the placebo (0 mg/m2/day) or the sirolimus medium dose (5
to 6 mg/m2/day) and high dose (7 to 13 mg/m2/day) groups. These
data indicate that sirolimus does not affect the apparent oral
clearance of CsA in a dose-dependent manner, as there was no
significant difference between placebo and high-dose administra-
tion. The dose-escalation study design which used different pa-
tients and different time periods may have contributed to the
apparently significant effect after low-dose administration. The
ANCOVA analysis of C55av values for all groups did not show
significant differences either before (P = 0.14) or after (P = 0.91)
sirolimus administration.
Effects of sirolimus treatment on liver function
Sirolimus-treated patients displayed normal values of SGOT
and SGPT throughout the study. The mean SGOT and SGPT
values before sirolimus treatment (20.9 13.2 and 22.9 20.2
IU, respectively) were similar to those of patients in the placebo-
treated and the control groups (Table 2). At the completion of the
study on day 15, there were also no statistically significant
differences between the transaminase levels of the patients in each
sirolimus-treated dose group versus those of patients in the
placebo-treated cohort (Table 2).
Discussion
The therapeutic benefits of CsA are at least partially offset by its
pleiotropic hepatic, neural, and, most importantly, renal toxicities
[2]. The renal injury may present as an acute functional impair-
ment or as a progressive, incompletely reversible deterioration.
Two strategies, combination therapy with azathioprine [241 or
Fig. 3. GFR values in sirolimus-treated
compared with placebo-treated patients before (U)
and after () drug administration. (A) The
entire group of sirolimus (RAPA)-treated
versus placebo-treated patients. (B) GFR values
before versus after administration of a 14-day
course of sirolimus treatment in patients
stratified into low (1 to 3 mg/rn2), medium (5 to
6 mg/rn2), and high (7 to 13 mg/m2) dose
groups.
Table 4. Mean systolic and diastolic blood pressure values of all
patients in the RAPA, placebo and historical control groups at entry
into and after completion of the study
Entry At day 15 At six weeks
Systolic blood pressurea
RAPA 132.3 17.6 140.3 20.4 132.5 15.3
Control 133.3 20.6 — 130.9 15.3
Placebo 129.7 16.5 146.0 25.0 142.2 18.5
Diastolic blood pressurea
RAPA 83.5 10.7 81.7 11.6 82.5 10.6
Control 86.8 12.9 — 82.8 12.2
Placebo 79.7 14.3 90.1 16.1 90.4 14
a All P values across time for each cohort were not significantly different
patient-individualized regimens based upon serial pharmacoki-
netic profiles [20], have failed to mitigate the renal toxicity. A
third potential approach to decreasing side effects seeks to exploit
the synergistic immunosuppressive actions of sirolimus, which
have been documented both in vitro using human lymphocytes and
in vivo in animal transplant models [12]. The present results
portend the success of the third strategy because there is little
overlap of the toxic side-effect spectra of cyclosporine and siroli-
mus.
The primary toxic side-effect of sirolimus appears to be a
reversible decrease in PLT and, to a lesser extent, WBC counts.
The drug's effect on PLT counts is dose-related; it occurred at
doses > 5 mg/rn2 and began at day 9. In fact, PLT values of <
150,000 cells/mm3 were present in six patients on day 9, 10
patients on day 12, and ii patients on day 15. These changes were
reversible by two weeks after discontinuation of sirolimus treat-
ment. In contrast, the WBC toxicity did not seem to be dependent
on dose. Indeed, the mean WBC value of each sirolimus group
never fell below the lower boundary of normal (4800 cells/mm3),
although 41% of the 29 sirolimus patients under treatment at day
15 had WBC counts below that level.
Myeloid effects of sirolimus, which are distinct from the non-
myelosuppressive toxic spectrum of CsA effects, have also been
observed in a mouse model [25], wherein administration of the
drug delayed recovery from leukopenia and thrombocytopenia
that had been induced by 5-fluoro-uracil (FU; 150 mg/kg i.v.). The
effect was reversible; all parameters normalized by seven days
after cessation of sirolimus treatment. In the present report
sirolimus inhibited steady state generation of platelet and myeloid
formed elements. In view of its capacity to disrupt the transduc-
tion of cytokine signals, it is possible that sirolirnus alters the in
vivo proliferative responses during both the stimulatory and
steady state phases of hematopoiesis. These effects may be due to
drug-induced inhibition of transduction of the signals induced by
cytokines, such as c-kit (KL) [26], granulocyte-colony stimulating
factor (G-CSF) [25], granulocyte-macrophage-colony stimulating
factor (GM-CSF) [27—29], interleukin (IL)-1 [30], IL-3 [31], IL-6
[32—341, and IL-Il [35—38]. Because the same gp 130 /3 chain [38]
is present in the IL-il receptor and in the IL-6 receptor, whose
signal transduction is inhibited by sirolimus [121, we hypothesize
that sirolimus inhibits the transduction of IL-il. This newly
discovered multifunctional hematopoietic cytokine acts synergis-
tically at least in vitro with KL [26], IL-3 [391 and IL-4. IL-Il
administration stimulates megakaryocytopoiesis in rodents and
non-human primates [26, 40—42], as well as reverses the throm-
bocytopenia secondary to high-dose chemotherapy in women
afflicted with advanced breast cancer [42]. The decreased WBC
count may relate to as-yet-undemonstrated effects of sirolimus to
inhibit proliferative stimulation by G-CSF, GM-CSF, and/or IL-3.
Sirolimus does not appear to exacerbate the renal toxicities of
CsA. Sirolimus treatment did not significantly affect the Sr and
GFR values compared with concurrently treated control and
placebo patients, a finding consistent with reports in experimental
animals. No adverse effects on renal function or histology [43]
were displayed by Sprague-Dawley rats treated with 16 day
courses of sirolimus at doses of up to 10 mg/kg. However,
long-term studies will be required to assess the impact of chronic
sirolimus therapy on CsA-induced renal dysfunction. In addition,
A
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Table 5. CsA steady-state pharmacokinetic parameters among RAPA dose groups
Parameter Unit
Study
day
RAPA dose mg/m2lday
Placebo
0
(N = 8)
Low
1—3
(N = 8)
Medium
5—6
(N = 8)
High
7—13
(N = 10)
Oral clearance (CL)/F)
mI/mm/kg
C5Sav
(ng/ml)
—1
14
—1
14
825 2.34
6.59 1.42
360 63
445 106
12.1 4.8a
12.7 4.9"
348 50C
339 93"
10.1 3.7
8.56 3.39
405 134
463 135
9.45 4.00
7.74 2.77
352 133
398 102
a The P values for baseline effects were 0.029 and 0.075 (low dose > placebo high), respectively
The P value for treatment was 0.029
C The P value for baseline effect was 0.91
d The P value for treatment was 0.14
sirolimus did not increase the blood pressure values of quiescent
transplant patients. The mean systolic and diastolic blood pres-
sure readings did not change significantly before, during or at the
completion of the study. After 14 days of treatment 23.33% (seven
patients) of the sirolimus- and 20% (two patients) of the placebo-
treated cohorts showed readings greater than 170/100 mm Hg. All
nine patients had a history of end-stage renal disease (ESRD) due
to hypertension. Only 10% of all of these patients required
additional anti-hypertensive medication after discontinuation of
the study drug.
Furthermore, sirolimus did not significantly potentiate the
hepatotoxicity of CsA. Although all patients in every group
displayed normal baseline SGOT and SGPT values, two patients
(6.66%) showed slightly increased SOOT (55.00 1.41), and
three patients (10%) slightly increased SGPT (55.67 4.04)
values. In two patients (1 in the low dose and 1 in the medium
dose groups) both SGOT and SGPT levels increased. The other
patient with increased SGPT was in the low dose group.
Lipid abnormalities, which are not uncommon in dialyzed
ESRD patients, are exacerbated by both CsA and steroid admin-
istration, thereby predisposing transplant recipients to accelerated
atherosclerosis [241. Two other factors that also may have con-
tributed to the increased hyperlipidemia were /3-blocker therapy
and the presence of diabetes mellitus. These characteristics were
displayed by 40% versus 46.6% and 23,33% versus 13.33% of the
sirolimus versus placebo group patients, respectively. Sirolimus
caused a dose-related increase in cholesterol values that was only
marginally statistically significant after accounting for baseline
differences. Although a two week course of sirolimus treatment
did not significantly increase triglyceride levels, it is possible that
these levels will be altered by chronic therapy.
Because the clinical utility of any drug combination depends not
only on its therapeutic, but also its toxic interactions, the prelim-
inary characterization of the side effects of sirolimus presented
herein is important because it fails to document significant
exacerbation of the renal toxicity of CsA. Therefore, the addition
of sirolimus to post-transplant treatment regimens may represent
an important step toward T cell selective immunosuppression.
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Appendix
Abbreviations are: AUC, area under the concentration-time curve;
CCB, calcium channel blockers; CsA, cyclosporine; GFR, glomerular
filtration rate; IL, interleukin; PLT, platelets; RAPA, sirolimus; Se,, serum
creatinine; SGOT, serum glutamic oxaloacetic transaminase; SGPT, se-
rum glutamic pyruvic transaminase; WBC, white blood cells.
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